Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

While this class of drugs becomes ever more prevalent, and the wide-ranging positive health outcomes become better known, ...

It's a big day for Novo Nordisk (NVO) as its CEO Lars Fruergaard Jørgensen testified Tuesday on Capitol Hill over the ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

Recent research easing suicidality concerns about GLP-1s and suggesting potential psychiatric benefit has led to a call for ...

When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit ...

The number of personal injury lawsuits centralized in a Pennsylvania court regarding the potentially harsh side effects of ...